{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:06:14Z","timestamp":1773353174696,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"DOI":"10.1186\/s12981-025-00701-3","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:43:24Z","timestamp":1741697004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV"],"prefix":"10.1186","volume":"22","author":[{"given":"Immaculate","family":"Nankya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Natukunda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Rutebarika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Matama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Basiimwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Arikod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faryad","family":"Muwabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Otike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"issue":"5","key":"701_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s11904-020-00522-1","volume":"17","author":"A Grimsrud","year":"2020","unstructured":"Grimsrud A, et al. Understanding Engagement in HIV programmes: how Health services can adapt to ensure no one is left behind. Curr HIV\/AIDS Rep. 2020;17(5):458\u201366.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"701_CR2","doi-asserted-by":"publisher","first-page":"e0245461","DOI":"10.1371\/journal.pone.0245461","volume":"16","author":"E Lopez-Varela","year":"2021","unstructured":"Lopez-Varela E, et al. Quantifying the gender gap in the HIV care cascade in southern Mozambique: we are missing the men. PLoS ONE. 2021;16(2):e0245461.","journal-title":"PLoS ONE"},{"issue":"3","key":"701_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1473-3099(10)70288-7","volume":"11","author":"I de Vincenzi","year":"2011","unstructured":"de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis. 2011;11(3):171\u201380.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"701_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cct.2010.09.008","volume":"32","author":"Safety","year":"2011","unstructured":"Safety. Effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre collaborative study rationale, design, and implementation challenges. Contemp Clin Trials. 2011;32(1):74\u201385.","journal-title":"Contemp Clin Trials"},{"key":"701_CR5","doi-asserted-by":"crossref","unstructured":"Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011; (7): p.Cd003510.","DOI":"10.1002\/14651858.CD003510.pub3"},{"issue":"7","key":"701_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1001\/jama.296.7.794","volume":"296","author":"I Thior","year":"2006","unstructured":"Thior I, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study. JAMA. 2006;296(7):794\u2013805.","journal-title":"JAMA"},{"issue":"2","key":"701_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jama.292.2.202","volume":"292","author":"TE Taha","year":"2004","unstructured":"Taha TE, et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA. 2004;292(2):202\u20139.","journal-title":"JAMA"},{"issue":"5","key":"701_CR8","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1086\/367898","volume":"187","author":"D Moodley","year":"2003","unstructured":"Moodley D, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187(5):725\u201335.","journal-title":"J Infect Dis"},{"issue":"1","key":"701_CR9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1086\/508869","volume":"44","author":"P Thistle","year":"2007","unstructured":"Thistle P, et al. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. Clin Infect Dis. 2007;44(1):111\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"701_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1177\/1757975919873653","volume":"27","author":"MDC Komakech","year":"2020","unstructured":"Komakech MDC. Under-the-Mango-Tree: a theatre-based male EMTCT engagement intervention in post-conflict northern Uganda. Glob Health Promot. 2020;27(3):113\u201321.","journal-title":"Glob Health Promot"},{"issue":"Suppl 1","key":"701_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1186\/s12879-019-4393-5","volume":"19","author":"AE Goga","year":"2019","unstructured":"Goga AE, et al. What will it take for the global plan priority countries in Sub-saharan Africa to eliminate mother-to-child transmission of HIV? BMC Infect Dis. 2019;19(Suppl 1):783.","journal-title":"BMC Infect Dis"},{"key":"701_CR12","doi-asserted-by":"crossref","unstructured":"Sturt AS, Dokubo EK, Sint TT. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev, 2010;(3):Cd008440.","DOI":"10.1002\/14651858.CD008440"},{"issue":"1","key":"701_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12879-022-07119-6","volume":"22","author":"FH Astawesegn","year":"2022","unstructured":"Astawesegn FH, et al. Trends and effects of antiretroviral therapy coverage during pregnancy on mother-to-child transmission of HIV in Sub-saharan Africa. Evidence from panel data analysis. BMC Infect Dis. 2022;22(1):134.","journal-title":"BMC Infect Dis"},{"key":"701_CR14","first-page":"pCd006734","volume":"20091","author":"T Horvath","year":"2009","unstructured":"Horvath T, et al. Interventions for preventing late postnatal mother-to-child transmission of HIV. Cochrane Database Syst Rev. 2009;20091:pCd006734.","journal-title":"Cochrane Database Syst Rev"},{"key":"701_CR15","unstructured":"UNAIDS. The path that ends AIDS. 2023."},{"key":"701_CR16","doi-asserted-by":"crossref","unstructured":"White AB et al. Antiretroviral interventions for preventing breast milk transmission of HIV. Cochrane Database Syst Rev, 2014. 2014(10): p. Cd011323.","DOI":"10.1002\/14651858.CD011323"},{"key":"701_CR17","unstructured":"UNAIDS. Start free stay free AIDS free. 2016."},{"issue":"11","key":"701_CR18","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1093\/infdis\/jiab223","volume":"224","author":"JR Millar","year":"2021","unstructured":"Millar JR, et al. Early initiation of antiretroviral therapy following in Utero HIV infection is Associated with low viral reservoirs but other factors determine viral rebound. J Infect Dis. 2021;224(11):1925\u201334.","journal-title":"J Infect Dis"},{"issue":"1","key":"701_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12889-020-09418-6","volume":"20","author":"A Alebel","year":"2020","unstructured":"Alebel A, et al. Mortality rate among HIV-positive children on ART in Northwest Ethiopia: a historical cohort study. BMC Public Health. 2020;20(1):1303.","journal-title":"BMC Public Health"},{"issue":"9","key":"701_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.7196\/SAMJ.2019.v109i9.13765","volume":"109","author":"F Moyo","year":"2019","unstructured":"Moyo F, et al. Monitoring diagnosis, retention in care and viral load suppression in children testing HIV polymerase chain reaction-positive in two districts in South Africa. S Afr Med J. 2019;109(9):686\u201392.","journal-title":"S Afr Med J"},{"issue":"1","key":"701_CR21","doi-asserted-by":"publisher","first-page":"e0246140","DOI":"10.1371\/journal.pone.0246140","volume":"16","author":"S Nabukeera","year":"2021","unstructured":"Nabukeera S, et al. Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda. PLoS ONE. 2021;16(1):e0246140.","journal-title":"PLoS ONE"},{"issue":"1","key":"701_CR22","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1186\/s12889-018-5964-x","volume":"18","author":"E Nasuuna","year":"2018","unstructured":"Nasuuna E, et al. Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda. BMC Public Health. 2018;18(1):1048.","journal-title":"BMC Public Health"},{"issue":"5","key":"701_CR23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/QAI.0000000000002291","volume":"83","author":"J Schroter","year":"2020","unstructured":"Schroter J, et al. Time to viral suppression in perinatally HIV-Infected infants depends on the viral load and CD4 T-Cell percentage at the start of treatment. J Acquir Immune Defic Syndr. 2020;83(5):522\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"701_CR24","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S2352-3018(18)30012-2","volume":"5","author":"S Shiau","year":"2018","unstructured":"Shiau S, et al. Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission? Lancet HIV. 2018;5(5):e250\u20138.","journal-title":"Lancet HIV"},{"key":"701_CR25","first-page":"23","volume":"14","author":"CM Tiruneh","year":"2022","unstructured":"Tiruneh CM, et al. Clinical non-adherence and its Associated factors among HIV-Positive Pediatric patients attending HIV Care in South Gondar Zone Public Health Facilities, Northwest Ethiopia, 2021. HIV AIDS (Auckl). 2022;14:23\u201332.","journal-title":"HIV AIDS (Auckl)"},{"key":"701_CR26","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1017\/S0950268821000637","volume":"149","author":"G van Liere","year":"2021","unstructured":"van Liere G, et al. High rate of loss to follow-up and virological non-suppression in HIV-infected children on antiretroviral therapy highlights the need to improve quality of care in South Africa. Epidemiol Infect. 2021;149:e88.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"701_CR27","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.1038\/s41598-020-62281-8","volume":"10","author":"G Wang","year":"2020","unstructured":"Wang G, et al. 90-90-90 cascade analysis on reported CLHIV infected by mother-to-child transmission in Guangxi, China: a modeling study. Sci Rep. 2020;10(1):5295.","journal-title":"Sci Rep"},{"issue":"8","key":"701_CR28","doi-asserted-by":"publisher","first-page":"e0256256","DOI":"10.1371\/journal.pone.0256256","volume":"16","author":"K Ashburn","year":"2021","unstructured":"Ashburn K, et al. A randomized controlled trial evaluating the effects of a family-centered HIV care model on viral suppression and retention in care of HIV-positive children in Eswatini. PLoS ONE. 2021;16(8):e0256256.","journal-title":"PLoS ONE"},{"issue":"2","key":"701_CR29","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2352-3018(21)00291-5","volume":"9","author":"CA Teasdale","year":"2022","unstructured":"Teasdale CA, et al. Estimates of the prevalence of undiagnosed HIV among children living with HIV in Eswatini, Lesotho, Malawi, Namibia, Tanzania, Zambia, and Zimbabwe from 2015 to 2017: an analysis of data from the cross-sectional Population-based HIV Impact Assessment surveys. Lancet HIV. 2022;9(2):e91\u2013101.","journal-title":"Lancet HIV"},{"issue":"8","key":"701_CR30","doi-asserted-by":"publisher","first-page":"e25168","DOI":"10.1002\/jia2.25168","volume":"21","author":"CA Teasdale","year":"2018","unstructured":"Teasdale CA, et al. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa. J Int AIDS Soc. 2018;21(8):e25168.","journal-title":"J Int AIDS Soc"},{"issue":"9","key":"701_CR31","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1016\/S2352-3018(22)00163-1","volume":"9","author":"P Amuge","year":"2022","unstructured":"Amuge P, et al. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022;9(9):e638\u201348.","journal-title":"Lancet HIV"},{"issue":"27","key":"701_CR32","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, et al. Dolutegravir as First- or second-line treatment for HIV-1 infection in children. N Engl J Med. 2021;385(27):2531\u201343.","journal-title":"N Engl J Med"},{"issue":"3","key":"701_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","volume":"19","author":"M Aboud","year":"2019","unstructured":"Aboud M, et al. Dolutegravir versus ritonavir-boosted LPV both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19(3):253\u201364.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"701_CR34","doi-asserted-by":"publisher","first-page":"ofac651","DOI":"10.1093\/ofid\/ofac651","volume":"9","author":"U Akpan","year":"2022","unstructured":"Akpan U, et al. Reaching viral suppression among people with HIV with suspected treatment failure who received enhanced adherence counseling in Southern Nigeria: a retrospective analysis. Open Forum Infect Dis. 2022;9(12):ofac651.","journal-title":"Open Forum Infect Dis"},{"key":"701_CR35","doi-asserted-by":"crossref","unstructured":"Diress G et al. Viral load suppression after enhanced adherence counseling and its predictors among high viral load HIV seropositive people in North Wollo Zone Public Hospitals, Northeast Ethiopia, 2019: Retrospective Cohort Study. AIDS Res Treat, 2020. 2020: p. 8909232.","DOI":"10.1155\/2020\/8909232"},{"issue":"1","key":"701_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12981-023-00513-3","volume":"20","author":"C Nakaye","year":"2023","unstructured":"Nakaye C, et al. Viral load suppression after intensive adherence counselling among adult people living with HIV at Kiswa health centre, Kampala: a retrospective cohort study. Secondary data analysis. AIDS Res Ther. 2023;20(1):18.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"701_CR37","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1186\/s12889-021-12366-4","volume":"21","author":"G Ndikabona","year":"2021","unstructured":"Ndikabona G, et al. Unsuppressed viral load after intensive adherence counselling in rural eastern Uganda; a case of Kamuli district, Uganda. BMC Public Health. 2021;21(1):2294.","journal-title":"BMC Public Health"},{"issue":"2","key":"701_CR38","doi-asserted-by":"publisher","first-page":"e0211326","DOI":"10.1371\/journal.pone.0211326","volume":"14","author":"T Bvochora","year":"2019","unstructured":"Bvochora T, et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: operational issues. PLoS ONE. 2019;14(2):e0211326.","journal-title":"PLoS ONE"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00701-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-025-00701-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-025-00701-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:43:28Z","timestamp":1741697008000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-025-00701-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["701"],"URL":"https:\/\/doi.org\/10.1186\/s12981-025-00701-3","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and approval from the National Council of Science and Technology were obtained (JC3617 and HS 2383, respectively).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This was obtained under the consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}